FR3003171B1 - Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire - Google Patents

Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Info

Publication number
FR3003171B1
FR3003171B1 FR1352360A FR1352360A FR3003171B1 FR 3003171 B1 FR3003171 B1 FR 3003171B1 FR 1352360 A FR1352360 A FR 1352360A FR 1352360 A FR1352360 A FR 1352360A FR 3003171 B1 FR3003171 B1 FR 3003171B1
Authority
FR
France
Prior art keywords
antibody composition
enhanced antibody
novel medicaments
enforcement
majority load
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1352360A
Other languages
English (en)
French (fr)
Other versions
FR3003171A1 (fr
Inventor
Guillaume Chevreux
Nicolas Bihoreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1352360A priority Critical patent/FR3003171B1/fr
Application filed by LFB SA filed Critical LFB SA
Priority to EP14709977.4A priority patent/EP2968533A1/fr
Priority to PCT/EP2014/055179 priority patent/WO2014140322A1/fr
Priority to CN201480024699.3A priority patent/CN105163758B/zh
Priority to JP2015562236A priority patent/JP2016512216A/ja
Priority to MX2015012812A priority patent/MX2015012812A/es
Priority to CA2907358A priority patent/CA2907358A1/fr
Priority to US14/776,725 priority patent/US20160046722A1/en
Priority to KR1020157029822A priority patent/KR20150132522A/ko
Priority to AU2014230134A priority patent/AU2014230134A1/en
Priority to BR112015023209A priority patent/BR112015023209A8/pt
Publication of FR3003171A1 publication Critical patent/FR3003171A1/fr
Application granted granted Critical
Publication of FR3003171B1 publication Critical patent/FR3003171B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR1352360A 2013-03-15 2013-03-15 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire Expired - Fee Related FR3003171B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR1352360A FR3003171B1 (fr) 2013-03-15 2013-03-15 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
KR1020157029822A KR20150132522A (ko) 2013-03-15 2014-03-14 주요 전하 아이소폼이 풍부한 항체 조성물을 포함하는 신규 의약품
CN201480024699.3A CN105163758B (zh) 2013-03-15 2014-03-14 包含富集主要电荷同工型的抗体组合物的药物
JP2015562236A JP2016512216A (ja) 2013-03-15 2014-03-14 主要電荷アイソフォームに富んだ抗体組成物を含む新規な薬剤
MX2015012812A MX2015012812A (es) 2013-03-15 2014-03-14 Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor.
CA2907358A CA2907358A1 (fr) 2013-03-15 2014-03-14 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
EP14709977.4A EP2968533A1 (fr) 2013-03-15 2014-03-14 Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
PCT/EP2014/055179 WO2014140322A1 (fr) 2013-03-15 2014-03-14 Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
AU2014230134A AU2014230134A1 (en) 2013-03-15 2014-03-14 Novel medicaments comprising an antibody composition enriched with predominant charge isoform
BR112015023209A BR112015023209A8 (pt) 2013-03-15 2014-03-14 novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma
US14/776,725 US20160046722A1 (en) 2013-03-15 2014-03-14 Novel medicaments comprising an antibody composition enriched with predominant charge isoform

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1352360A FR3003171B1 (fr) 2013-03-15 2013-03-15 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Publications (2)

Publication Number Publication Date
FR3003171A1 FR3003171A1 (fr) 2014-09-19
FR3003171B1 true FR3003171B1 (fr) 2015-04-10

Family

ID=48771615

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1352360A Expired - Fee Related FR3003171B1 (fr) 2013-03-15 2013-03-15 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Country Status (11)

Country Link
US (1) US20160046722A1 (enExample)
EP (1) EP2968533A1 (enExample)
JP (1) JP2016512216A (enExample)
KR (1) KR20150132522A (enExample)
CN (1) CN105163758B (enExample)
AU (1) AU2014230134A1 (enExample)
BR (1) BR112015023209A8 (enExample)
CA (1) CA2907358A1 (enExample)
FR (1) FR3003171B1 (enExample)
MX (1) MX2015012812A (enExample)
WO (1) WO2014140322A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6454547B2 (ja) 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
DK3451820T3 (da) 2016-05-04 2021-01-18 Delaval Holding Ab Kassette og konnektor til en pattekop samt pattekop, der omfatter kassetten og konnektoren
FR3053688B1 (fr) * 2016-07-06 2026-05-01 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Mutants fc a activite fonctionnelle amelioree
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
SG11202107941TA (en) 2019-01-23 2021-08-30 Encefa Cd31 competitors and uses thereof
US20200369720A1 (en) * 2019-05-23 2020-11-26 Regeneron Pharmaceuticals, Inc. Characterization of domain-specific charge variants of antibodies
WO2021057726A1 (zh) * 2019-09-23 2021-04-01 南开大学 利用哺乳动物展示筛选FcγR特异性结合Fc
PL4401842T3 (pl) 2021-09-16 2025-11-24 Aboleris Pharma Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
CN114236010A (zh) * 2021-12-18 2022-03-25 苏州莱奥生物技术有限公司 一种生物活性药物的药代动力学分析方法
CN115073548A (zh) * 2022-08-01 2022-09-20 上海蓝析生物技术有限公司 一种用于重组蛋白药物电荷异构体制备的缓冲体系

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209392B1 (pl) * 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
EP1553975B8 (en) * 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
BRPI0315295C1 (pt) * 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
CA2512729C (en) * 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
FR2861078B1 (fr) * 2003-10-16 2007-09-21 Lab Francais Du Fractionnement NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
JP6454547B2 (ja) * 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節

Also Published As

Publication number Publication date
BR112015023209A2 (pt) 2017-07-18
JP2016512216A (ja) 2016-04-25
US20160046722A1 (en) 2016-02-18
EP2968533A1 (fr) 2016-01-20
CN105163758A (zh) 2015-12-16
AU2014230134A1 (en) 2015-10-29
CA2907358A1 (fr) 2014-09-18
FR3003171A1 (fr) 2014-09-19
MX2015012812A (es) 2016-05-09
BR112015023209A8 (pt) 2018-01-23
CN105163758B (zh) 2017-11-17
KR20150132522A (ko) 2015-11-25
WO2014140322A1 (fr) 2014-09-18

Similar Documents

Publication Publication Date Title
FR3003171B1 (fr) Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
FR25C1038I1 (fr) Conjugue anticorps anti-trop2-medicament
EP2961774A4 (en) ALPHA SYNUCLEIN ANTIBODIES AND USES THEREOF
EP2783849A4 (en) encapsulating
EP2989542A4 (en) DEVELOPMENT PLATFORM FOR INTELLIGENT MOBILE APPLICATIONS
EP2812809A4 (en) FRAMEWORK FOR CLOUD COMPUTING SERVICES
EP2841458A4 (en) MODIFIED ANTIBODY REGIONS AND USE THEREOF
EP2962216A4 (en) COMMON USE OF APPLICATION STATES
EP2958944A4 (en) NOVEL ANTIBODY CONJUGATES AND USES THEREOF
EP2936733A4 (en) CONNECTIVE BUS FOR SAFE MOBILE APPS
BR112014029403A2 (pt) conjugados, anticorpo e formulação farmacêutica
EP2854838A4 (en) PEGYLATED OXM VARIANTS
EP2989214A4 (en) IN SITU INTERACTION DETERMINATION
EP2937909A4 (en) PACKAGING FILM
IL237345A0 (en) Antibody and drug conjugates (adc) that bind to 158p1d7 proteins, preparations containing them and their uses
FR3000927B1 (fr) Structure de couvercle coulissant d'un rangement et vehicule la comprenant
EP2826790A4 (en) GREMLIN-1 ANTIBODY
EP2810965A4 (en) PFROPOPOPOLYMER COMPOSITION BASED ON ASA
EP2913686A4 (en) LAST TESTER
EP2844290A4 (en) NOVEL ANTIBODIES
EP2746394A4 (en) ANTIBODY AND ANTIBODY COMPOSITION
DK3556350T3 (da) Farmaceutisk præparat indeholdende et antiviralt aktivt dihydroquinazolinderivat med s-konfiguration i 4-stillingen
EP2759551A4 (en) ANTIBODIES AGAINST AFFINITY COMPLEX
EP2857000A4 (en) COSMETIC COMPOSITION WITH AN EMULSION
EP2805996A4 (en) Thermoplastic Elastomer Composition

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20191106